Faruqi & Faruqi said it is investigating potential securities claims on behalf of investors in Rezolute Inc. following a sharp selloff in the company’s shares after disappointing topline results from its Phase 3 sunRIZE trial of ersodetug for congenital hyperinsulinism. The firm alleges investors who suffered significant losses in Rezolute stock or options may have legal rights and is seeking to speak with affected shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602190951PRIMZONEFULLFEED9657199) on February 19, 2026, and is solely responsible for the information contained therein.